Cargando…

Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System

INTRODUCTION: The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic. OBJECTIVES: The objective of the current stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nzolo, Didier, Anto, Francis, Hailemariam, Sarah, Bakajika, Didier, Muteba, Daniel, Makenga, Jean-Claude, Mesia, Gautier, Nsibu, Celestin, Mampunza, Samuel, Tona, Gaston
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567455/
https://www.ncbi.nlm.nih.gov/pubmed/28600751
http://dx.doi.org/10.1007/s40801-017-0110-0
_version_ 1783258736240885760
author Nzolo, Didier
Anto, Francis
Hailemariam, Sarah
Bakajika, Didier
Muteba, Daniel
Makenga, Jean-Claude
Mesia, Gautier
Nsibu, Celestin
Mampunza, Samuel
Tona, Gaston
author_facet Nzolo, Didier
Anto, Francis
Hailemariam, Sarah
Bakajika, Didier
Muteba, Daniel
Makenga, Jean-Claude
Mesia, Gautier
Nsibu, Celestin
Mampunza, Samuel
Tona, Gaston
author_sort Nzolo, Didier
collection PubMed
description INTRODUCTION: The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic. OBJECTIVES: The objective of the current study was to describe the central and peripheral nervous system disorders that occurred after mass administration of ivermectin in Democratic Republic of Congo (DRC). METHODS: This is a retrospective descriptive study involving a review of data on adverse events related to mass administration of ivermectin. Data on reported serious adverse events following mass administration of ivermectin in the DRC were extracted from the World Health Organization (WHO) Global individual case safety report (ICSR) database (VigiBase). The review covered the period 2009–2013 and focused on central and peripheral nervous system disorders. Relevant demographic, clinical, and parasitological data, including age, sex, area of residence, adverse events, and parasite density were extracted. Descriptive statistics were analyzed using Stata 12. RESULTS: A total of 52 ICSRs related to ivermectin intake were available in VigiBase, with 51 (98.1%) from the Province of Equateur. All patients had central and peripheral nervous system disorders; 25 (48.1%) had altered mental status. Of these, 23 (92.0%) satisfied the criteria for “probable/possible Loa loa encephalopathy temporally related to mectizan(®)” (PLERM). The most frequent nervous system disorders among patients with PLERM were coma (74%), stupor (30%), headache (22%), and abnormal gait (22%). There were, on average, 2149.1 microfilariae per ml (mf/ml) in peripheral blood [95% confidence interval (CI) 463.6–3834.6; n = 23]. Post-treatment, 61% of PLERM cases had <1000 L. loa mf/ml of blood. One patient had microfilariae in the cerebrospinal fluid rather than the peripheral blood. We found 21.4% co-infection with Plasmodium falciparum and 4% mortality. CONCLUSION: PLERM may occur at even low peripheral blood concentrations of microfilaria.
format Online
Article
Text
id pubmed-5567455
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-55674552017-09-11 Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System Nzolo, Didier Anto, Francis Hailemariam, Sarah Bakajika, Didier Muteba, Daniel Makenga, Jean-Claude Mesia, Gautier Nsibu, Celestin Mampunza, Samuel Tona, Gaston Drugs Real World Outcomes Original Research Article INTRODUCTION: The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic. OBJECTIVES: The objective of the current study was to describe the central and peripheral nervous system disorders that occurred after mass administration of ivermectin in Democratic Republic of Congo (DRC). METHODS: This is a retrospective descriptive study involving a review of data on adverse events related to mass administration of ivermectin. Data on reported serious adverse events following mass administration of ivermectin in the DRC were extracted from the World Health Organization (WHO) Global individual case safety report (ICSR) database (VigiBase). The review covered the period 2009–2013 and focused on central and peripheral nervous system disorders. Relevant demographic, clinical, and parasitological data, including age, sex, area of residence, adverse events, and parasite density were extracted. Descriptive statistics were analyzed using Stata 12. RESULTS: A total of 52 ICSRs related to ivermectin intake were available in VigiBase, with 51 (98.1%) from the Province of Equateur. All patients had central and peripheral nervous system disorders; 25 (48.1%) had altered mental status. Of these, 23 (92.0%) satisfied the criteria for “probable/possible Loa loa encephalopathy temporally related to mectizan(®)” (PLERM). The most frequent nervous system disorders among patients with PLERM were coma (74%), stupor (30%), headache (22%), and abnormal gait (22%). There were, on average, 2149.1 microfilariae per ml (mf/ml) in peripheral blood [95% confidence interval (CI) 463.6–3834.6; n = 23]. Post-treatment, 61% of PLERM cases had <1000 L. loa mf/ml of blood. One patient had microfilariae in the cerebrospinal fluid rather than the peripheral blood. We found 21.4% co-infection with Plasmodium falciparum and 4% mortality. CONCLUSION: PLERM may occur at even low peripheral blood concentrations of microfilaria. Springer International Publishing 2017-06-09 /pmc/articles/PMC5567455/ /pubmed/28600751 http://dx.doi.org/10.1007/s40801-017-0110-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Nzolo, Didier
Anto, Francis
Hailemariam, Sarah
Bakajika, Didier
Muteba, Daniel
Makenga, Jean-Claude
Mesia, Gautier
Nsibu, Celestin
Mampunza, Samuel
Tona, Gaston
Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System
title Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System
title_full Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System
title_fullStr Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System
title_full_unstemmed Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System
title_short Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System
title_sort central and peripheral nervous system disorders following ivermectin mass administration: a descriptive study based on the democratic republic of congo pharmacovigilance system
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567455/
https://www.ncbi.nlm.nih.gov/pubmed/28600751
http://dx.doi.org/10.1007/s40801-017-0110-0
work_keys_str_mv AT nzolodidier centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT antofrancis centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT hailemariamsarah centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT bakajikadidier centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT mutebadaniel centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT makengajeanclaude centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT mesiagautier centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT nsibucelestin centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT mampunzasamuel centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem
AT tonagaston centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem